1. Home
  2. QDEL vs JANX Comparison

QDEL vs JANX Comparison

Compare QDEL & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuidelOrtho Corporation

QDEL

QuidelOrtho Corporation

HOLD

Current Price

$11.89

Market Cap

989.5M

Sector

Health Care

ML Signal

HOLD

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$17.29

Market Cap

975.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QDEL
JANX
Founded
1979
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
989.5M
975.7M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
QDEL
JANX
Price
$11.89
$17.29
Analyst Decision
Hold
Buy
Analyst Count
4
13
Target Price
$28.25
$47.00
AVG Volume (30 Days)
1.2M
781.8K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
45.35
N/A
EPS
N/A
N/A
Revenue
$2,730,200,000.00
$10,000,000.00
Revenue This Year
$3.51
N/A
Revenue Next Year
$3.86
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.92
$12.12
52 Week High
$35.58
$35.34

Technical Indicators

Market Signals
Indicator
QDEL
JANX
Relative Strength Index (RSI) 33.35 48.13
Support Level $11.37 $13.09
Resistance Level $12.85 $19.14
Average True Range (ATR) 0.75 0.81
MACD -0.18 -0.05
Stochastic Oscillator 5.63 16.45

Price Performance

Historical Comparison
QDEL
JANX

About QDEL QuidelOrtho Corporation

QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Share on Social Networks: